Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 5321 Results suggest a highly potent nextgeneration treatment that could offer greater efficacy with less frequent dosing SRP5051 dosed monthly at 30 mgkg delivered mean exon skipping of 1079 and mean dystrophin expression of 655 consistently higher than the other SRP5051 dosing cohorts at 12 weeks and weekly eteplirsen at 24 weeks Sareptas predictive model indicates that SRP5051 at 30 mgkg will achieve greater than 10 dystrophin with monthly chronic dosing CAMBRIDGE Mass May 03 2021 GLOBE NEWSWIRE  Sarepta Therapeutics Inc NASDAQSRPT the leader in precision genetic medicine for rare diseases today announced positive results from Part A of the MOMENTUM study Study 5051201 a global Phase 2 multiascending dose clinical trial of SRP5051 its nextgeneration peptide phosphorodiamidate morpholino oligomer PPMO treatment for patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping